scholarly journals B-Cell Lymphoma of the Mandible: A Case Report

2008 ◽  
Vol 2 ◽  
pp. CMO.S366
Author(s):  
Ali Adouani ◽  
Jed Bouguila ◽  
Yassine Jeblaoui ◽  
Mehdi Ben Aicha ◽  
Mouhamed Ali Abdelali ◽  
...  

Introduction The mandible is an infrequent localisation of primary osseous non-Hodgkin's lymphomas. Few cases of mandibular non-Hodgkin's lymphomas (NHL) have been reported. Case Report A rare condition of primary malignant non-Hodgkin's lymphoma of the mandible in 53-year-old man, was reported at the Department of Maxillofacial and Plastic Surgery in Charles Nicolle Hospital (Tunis, Tunisia). Histologic and Immunohistochemical (IHC) examination Confirmed a B-Cell lymphoma. Discussion The purpose of this report is to describe this rare case of NHL of the mandible, explore the diagnosis and workup, and discuss treatment strategies. In this localisation, neither the clinical features nor the radiologic appearances are often pathognomonic. Conclusion Particular care must be taken to consider lymphoma in the differential diagnosis because this uncommon lesion can pose significant diagnostic problems and is frequently misdiagnosed.

2017 ◽  
Vol 10 (1) ◽  
pp. 356-360
Author(s):  
Miodrag Vrbic ◽  
Ivan Petkovic ◽  
Svetislav Vrbic ◽  
Maja Jovanovic ◽  
Aleksandar Rankovic ◽  
...  

Introduction: HIV-infected patients are affected significantly more frequently by all types of lymphoma, with diffuse large B-cell lymphoma (DLBCL) as the most prevalent histological type. Since the introduction of combination antiretroviral therapy (cART) morbidity and mortality of DLBCL has been markedly reduced, which is primarily interpreted as a result of the drug-mediated immune reconstitution. Case Report: We present a previously healthy, 44-year-old HIV-infected man with DLBCL of the oral cavity, treated with immunochemotherapy and cART. During HIV-directed treatment, despite the successful virologic response, a satisfactory immunological response was not achieved. However, the patient had a 2-year complete remission after first-line treatment of DLBCL. Conclusion: Response to cART strongly predicts outcome in patients with DLBCL. Close monitoring of HIV-directed therapy efficacy, especially as to achievement of successful virologic response, independently associated with prolonged survival, is essential for estimating future DLBCL treatment strategies.


2021 ◽  
Vol 8 (3) ◽  
pp. 220-222
Author(s):  
Mustafa Ozan Horsanalı ◽  
Gürol Akan ◽  
Saniye Sevim Tuncer

Chirurgia ◽  
2017 ◽  
Vol 112 (4) ◽  
pp. 477 ◽  
Author(s):  
Adelina Birceanu Corobea ◽  
Adrian Dumitru ◽  
Maria Sajin ◽  
Radu Poenaru ◽  
Ana Puşcaşu ◽  
...  

2020 ◽  
Vol 16 (4) ◽  
pp. 24
Author(s):  
K. Dzhambazov ◽  
St. Konsulov ◽  
M. Rakadzieva ◽  
S. Konsulov

2014 ◽  
Vol 133 (2) ◽  
pp. 221-225 ◽  
Author(s):  
Michael Mian ◽  
Ines Wasle ◽  
Stefan Gritsch ◽  
Wolfgang Willenbacher ◽  
Michael Fiegl

Primary lymphoma of the lung or pleural is a very rare condition. Due to the outdated literature data, the approximate occurrence of primary and secondary lung and/or pleural involvement according to the most common B cell lymphoma entities is unknown. To answer this open question in Austria, we screened the Tyrolean registry for B cell non-Hodgkin's lymphomas regarding primary and secondary lung involvement. Of 854 patients affected by B cell lymphoma, 7.5% had lung/pleural disease. This organ was the primary site in only 0.7%, while a secondary involvement was registered in 6.8%. Most of them were affected by diffuse large B cell lymphoma (DLBCL; 29/368, 8%) followed by follicular lymphoma (7/188, 4%), mantle cell lymphoma (7/57, 12%), mucosa-associated tissue lymphoma (10/37, 27%), posttransplant lymphoproliferative disease (6/24, 25%), Burkitt lymphoma (3/19, 16%), other lymphomas (1/32, 3%) and Richter transformation (1/11, 9%). Moreover, primary lung/pleural lymphoma is one of the rarest neoplasias affecting the lung, accounting for only 0.4% of cases. Lung/pleural involvement is a very rare condition among B cell lymphomas since it mainly occurs in the setting of a generalized disease. A large majority of patients with secondary organ involvement are affected by DLBCL and have similar clinical features at diagnosis to others with advanced-stage disease. © 2014 S. Karger AG, Basel


Sign in / Sign up

Export Citation Format

Share Document